Court rejects Lilly’s challenge of competitor’s patents on migraine drug
Eli Lilly and Co.’s treatment Emgality and Teva Pharmaceutical’s drug Ajovy were approved within months of each other in 2018.
Drug discovery
Articles
Indy startup Outpost Medicine draws in big money to develop drug therapies
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
New Lilly R&D chief planning blitz of drug launches
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
Another experimental Alzheimer’s drug fails as Eli Lilly, Astra halt tests
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
Lilly signs licensing deal with biotech startup for diabetes drug
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
FDA opens new path for Alzheimer’s therapy as failures mount
The Food and Drug Administration proposal will create new opportunities for drugmakers after repeated failures from companies including Indianapolis-based Eli Lilly and Co.
Lilly looks to boost pipeline with drug partnerships
A slimmed-down Eli Lilly and Co., thousands of employees lighter after its biggest restructuring in nearly a decade, is now looking high and low for deals to bulk up its drug pipeline.
Pfizer to end Alzheimer’s research, cut 300 jobs
Pfizer said it will continue its support of potential blockbuster drug tanezumab, a late-stage pain treatment in development with Indianapolis-based Eli Lilly and Co.
Assembly Biosciences’ market value surges to nearly $1B, despite red ink
The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.
Tangled incentives push drugmakers away from opioid solutions
Pharmaceutical companies have introduced medicines to treat dependence, reverse overdoses and deal with opioid side effects. But few effective and economically viable alternatives to addictive painkillers have emerged from the laboratory.
FDA approving drugs at accelerated pace
Thirty-four new drugs—treating everything from cancer to rare genetic diseases—have been approved so far this year. That’s on pace to nearly double last year’s approvals.
Struggling Endocyte spending millions for rights to prostate-cancer drug
After struggling for more than 20 years to develop cancer drugs without success, West Lafayette-based Endocyte Inc. is pausing it own R&D efforts to concentrate on a potential blockbuster drug from a German chemical company.
Lilly insulin prices come under microscope
Over the past 20 years, while the price of a gallon of milk climbed 23 percent and the sticker on a Dodge Caravan minivan rose 21 percent, the list price of the insulin Humalog shot up 1,157 percent.
Lilly, Pfizer get boost for non-opioid pain drug
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
High court ruling speeds up generic biotech drug approval
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
Wall Street punishes Lilly for latest drug setback; analysts grasp for answers
News that federal regulators rejected Lilly’s drug for arthritis sent the stock tumbling more than 5 percent Monday, and sent surprised analysts searching for answers.
Lilly’s rheumatoid arthritis pill rejected by regulators
The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller.
Merck stops Alzheimer’s study after ‘no chance’ of benefit
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Indy-founded drug firm lands nearly $23M to fight rare disease
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.